FRANKFURT, Nov 12 (Reuters) - Bayer on Wednesday said it expected higher one-off burdens in 2025 from provisions for litigations and for buying out executives in its ongoing restructuring programme.

In a statement, the German maker of drugs, seeds and crop chemicals said it now expects special items to drag earnings before interest, tax, depreciation and amortisation (EBITDA) to between 3.5 billion euros ($4.08 billion) and 4 billion euros, worse than a previous forecast range of 2.5 billion-3.5 billion.

Sign up here.

It also reported that third-quarter adjusted EBITDA rose 20.8%, citing gains at the Crop Science division and reconciliation effects in accounting.

Quarterly EBITDA, adjusted for special items, came in at 1.51 billion euros ($1.76 billion), above the 1.28 billion euros expected on average by analysts according to a poll posted on the company's website.

($1 = 0.8575 euros)

https://www.reuters.com/business/healthcare-pharmaceuticals/bayers-third-quarter-adjusted-profit-beats-market-view-2025-11-12/